Gilead Sciences, Inc. is a research-based biopharmaceutical company that researches, develops, and sells innovative medicines. Primarily in the professional, scientific, and technical services industry, Gilead focuses on treating human immunodeficiency virus (HIV), liver diseases like hepatitis B virus infection and chronic hepatitis C virus infection, serious cardiovascular conditions, etc. Gilead uses FDA-certified suppliers to obtain certain supplies and products to manufacture prototypes of their drugs. They then use third-party manufacturers, which are independent entities, to manufacture sufficient quantities of any product that they create. Gilead then often undergoes clinical studies to ensure that the drug works effectively. Once this is confirmed, Gilead primarily sells to wholesalers such as Cardinal Health Inc., McKesson Corp. and AmerisourceBergen Corp. who distribute medicine to hospitals and people affected with viral diseases such as Hepatitis B and Hepatitis C. Lastly, Gilead operates in North and South America as well as in Europe and Asia-Pacific.
Pfizer Inc. is a biopharmaceutical company that was established in 1942 in the state of Delaware and is currently headquartered out of New York City, it is a global company that provides medicine to over 150 countries. As a research biopharmaceutical company, Pfizer Inc. is constantly innovating to find better treatments, to promote wellness, to find cures to diseases, to create new vaccines, for both humans and animals. Pfizer produces products to aid in the treatment of illness in the medical disciplines: immunology, oncology, cardiology, dialectology, endocrinology, and neurology. In addition, to manufacturing pharmaceuticals products, Pfizer promotes nutrition and a variety of nutrition products. Pfizer distributes their products worldwide through supplementary relations with other pharmaceutical companies, healthcare providers, communities, and governments who help Pfizer maintain their mission to provide affordable and safe healthcare around the world. In comparison to Gilead Science Inc., both companies are very similar companies, in the respect that they are are research based pharmaceutical companies and are a part of the same industry. As well, both Pfizer and Gilead’s products treat similar illnesses and diseases across the world. A key difference is Gilead does not create products to treat animals, where a big portion of Pfizer is dedicated to creating products for animals and promoting nutrition.
- Comparative Analysis of Gilead v. Pfizer Inc.
Gilead Sciences, Inc. saw little to no significant changes in its revenue from year to year. It remained relatively steady and continued to see positive year to year percent change in revenue. In terms of numbers, Gilead’s revenue increased from $7,011.38 million in 2009 to 11,201.69 million in 2013. On the other hand, Pfizer continually saw its revenue decrease from year to year indicated by constant negative percent change in revenue from 2010 to 2013. Pfizer’s revenue decreased from $67,057 million dollars in 2010 to $51,584 million dollars in 2013.
In addition to a consistent decrease in revenue for Pfizer, Pfizer has been downsizing its number of manufacturing sites. It went from 81 in 2009 to 56 in 2013. Additionally, Pfizer originally had 116,500 employees in 2009 and currently only has 77,700 employees as of 2013. Pfizer has also decreased its spending in terms of research and development, a key component to any biopharmaceutical company. It spent $8,681 million in 2011 and only $6,678 million in 2013. On the contrary, Gilead continually hires more workers and places an emphasis on research and development, demonstrated by the uptick in the capital spent on research and development. Gilead has grown in employee size from 3,800 employees in 2009 to 6,100 employees in 2013. Furthermore, Gilead has increased its spending on research and development, going from $939 million to $2,119 billion in the span of five years (from 2009 to 2013).
All in all, Gilead seems to be growing whereas Pfizer seems to be downsizing and decreasing in size.
- According to Gilead Sciences Inc.’s website, the goal of the company is “ to address unmet medical needs for patients living with life-threatening diseases around the world.” In order to maintain this mission, Gilead has partnered with other entities, including: science, academia, business and local communities in an effort to develop innovative medical solutions to life threatening diseases in the most cost effective and safe conscious method possible. Some diseases they are seeking medical treatments are: HIV, Aids, liver diseases, cancer and respiratory and cardiovascular diseases. In order to effectively reach and treat all of these diseases, Gilead’s plan of action is to continually increase the size of their company. In 2010, Gilead planned on increasing its workforce from by 1,700 employees within a few years, and from 2010 to 2013, its workforce increased by 2,100 employees. Gilead has been consistent with their statistics because they continuously put in money towards research and development and hiring new workers. By doing so, they have seen a positive percent change in revenue as well as net income. By adding more employees and putting more money into research and development, Gilead has been expanding the number of diseases they tackle. They’ve acquired multiple therapeutic companies and have recently been expanding into respiratory therapeutics. They educate all 7,000 employees through extensive training programs to adhere to the legal and ethical standards required by business conduct. Gilead plans to continually expand as they set a goal in 2013, to expand their main Foster City campus by 72.59 acres and hire out 5000 potential new employees.